Most cancer-associated deaths occur due to metastasis, yet our understanding of metastasis
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …

Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes
due to high risk of metastasis and resistance to treatment. In breast cancer, CD44+ CD24 …

Cell plasticity and neuroendocrine differentiation in prostate and lung adenocarcinomas are
one of the major reasons for therapeutic resistance to targeted therapy. Whether and how …

Due to rising incidence rates of liver cancer and worries about the toxicity of current
chemotherapeutic medicines, the hunt for further alternative methods to treat this malignancy …

Cancer cells are plastic–they can assume a wide range of distinct phenotypes. Plasticity is
integral to cancer initiation and progression, as well as to the emergence and maintenance …

Patient-derived organoids (PDOs) can model personalized therapy responses; however,
current screening technologies cannot reveal drug response mechanisms or how tumor …

Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic
resistance. Despite its importance, measures of ITH are still not incorporated into clinical …